Knowledge of the expression and function of glucose transporters on the human cerebral and cerebral barrier is essential to predict the penetration of the drug BBB and to design strategies to improve drug delivery to intracranial tumors, with significantly lower levels of SLC2A1 protein and the same in SLC2A3 in GBM microvascular-targeted proteomics [13]. The gene discussed is SLC2A3; the disease is glioblastoma.